Box News

Vitamin B5 in Sensitive Tissues and Neurological Health

Beyond its well-known role in skin care and energy metabolism, vitamin B5 and its derivative D-panthenol have significant effects on the body’s delicate mucosal surfaces and on the brain. Research into these areas reveals how critical pantothenic acid is for tissues that rely on rapid repair and for the proper functioning of the nervous system. Two distinct bodies of evidence, one from everyday clinical care and one from the study of a rare genetic disease, shed light on these important aspects.

Supporting the Eyes and Nasal Passages

D-panthenol is a common ingredient in eye drops designed to relieve dryness and support healing of the cornea, the transparent outer layer of the eye. The surface of the eye is a mucous membrane that relies on a stable tear film and a healthy layer of epithelial cells. In conditions where the cornea is damaged, such as after minor injuries, surgery, or in chronic dry eye disease, dexpanthenol can accelerate repair. A controlled clinical study found that artificial tears containing dexpanthenol improved the healing of superficial corneal wounds more effectively than the same solution without the vitamin. The mechanism involves enhanced migration and proliferation of corneal epithelial cells, as well as increased moisture retention due to the water-binding properties of the converted pantothenic acid. This makes D-panthenol a valuable supportive agent following procedures like laser eye surgery and for people with persistent dry eye symptoms.

A similar principle applies inside the nose. Nasal sprays containing dexpanthenol are used to treat rhinitis sicca, a condition marked by chronic dryness, crusting, and irritation of the nasal lining. The inner nose is lined with a mucous membrane that must stay moist to filter, warm, and humidify incoming air. When this lining becomes dry and atrophic, it is prone to bleeding and infection. In a randomized trial, a dexpanthenol nasal spray was shown to significantly reduce crusting, dryness, and the need for nasal cleaning in patients with rhinitis sicca compared to a saline-only spray. Surgeons also recommend dexpanthenol after nasal operations to support the regeneration of the mucosal tissue and to keep the healing area moist, which can lessen discomfort and the risk of scarring.

The Crucial Role of Pantothenic Acid in the Brain

The absolute necessity of vitamin B5 for brain health is dramatically illustrated by a rare inherited condition called pantothenate kinase-associated neurodegeneration, or PKAN. This disorder is caused by mutations in the gene that codes for pantothenate kinase 2, the enzyme responsible for the first step in converting pantothenic acid from the diet into coenzyme A. When the enzyme is defective, the brain cannot produce sufficient coenzyme A, a molecule vital for energy production and fatty acid metabolism in neurons. As a result, iron accumulates abnormally in specific brain regions, particularly the globus pallidus, leading to a progressive movement disorder characterized by severe muscle spasms, rigidity, and difficulties with walking and speech. This condition makes clear that while the body can obtain pantothenic acid from food, it is useless for brain cells if they cannot process it into its active form.

Because PKAN involves a block in vitamin activation rather than a simple dietary lack, giving high-dose pantothenic acid has not been an effective treatment. The defective kinase remains the bottleneck, and excess B5 cannot force its way through. This has led researchers to explore compounds that can bypass the faulty enzyme and supply coenzyme A precursors downstream. Pantethine, a stable dimeric form of a natural coenzyme A precursor, and fosmetpantotenate, a specially designed prodrug, have been investigated for this purpose. A randomized clinical trial of fosmetpantotenate in individuals with PKAN did not meet its primary goal of slowing disease progression, but the search for effective therapies continues. The very existence of such an intense research effort highlights how fundamental intact vitamin B5 metabolism is for the survival of neurons involved in controlling movement.

Final Remarks

The versatile nature of D-panthenol allows it to soothe and restore the delicate mucosal tissues of the eye and nose, aiding recovery where moisture and rapid cell renewal are essential. At the same time, the catastrophic neurological consequences that follow when the body cannot use pantothenic acid properly reveal the profound, non-negotiable requirement the brain has for its active coenzyme form. Together, these insights expand the picture of vitamin B5 from a simple dietary essential to a guardian of surface tissues and a critical player in the central nervous system.

References

Göbbels, M., & Gross, D. (1990). Clinical study of a dexpanthenol-containing artificial tears solution in dry eye conditions. Klinische Monatsblatter fur Augenheilkunde, 197(2), 119-123.

Gregory, A., & Hayflick, S. J. (2020). Pantothenate Kinase-Associated Neurodegeneration. In M. P. Adam et al. (Eds.), GeneReviews. University of Washington, Seattle.

Kehrl, W., Sonnemann, U., & Dethlefsen, U. (2003). Advantage of a dexpanthenol-containing nasal spray in comparison to saline spray for rhinitis sicca. Laryngo-Rhino-Otologie, 82(4), 266-271.

Klopstock, T., Tricta, F., Neumayr, L., Karin, I., Zorzi, G., Fradette, C., ... & Hayflick, S. J. (2019). Fosmetpantotenate randomized trial in pantothenate kinase-associated neurodegeneration. Movement Disorders, 34(10), 1534-1543.

(Source : DeepSeek)

Vitamin B5: An Essential Nutrient

Vitamin B5, known scientifically as pantothenic acid, is a water-soluble vitamin that plays a central role in human health. Its name comes from the Greek word “pantos,” meaning everywhere, because it is found in a wide variety of foods. Within the body, this vitamin is a building block for coenzyme A, a molecule that is essential for life. Coenzyme A is needed to break down fats, carbohydrates and proteins from food and turn them into energy. It also helps produce cholesterol, steroid hormones, the neurotransmitter acetylcholine, and the oxygen-carrying molecule hemoglobin. Without enough vitamin B5, these fundamental processes would slow down, affecting nearly every tissue. (National Institutes of Health, 2021; European Food Safety Authority, 2014)

The Special Role of D-Panthenol

D-Panthenol is the alcohol form of pantothenic acid, sometimes called provitamin B5. When applied to the skin or ingested, the body rapidly converts D-panthenol into active pantothenic acid. This form is remarkably stable in water-based products and absorbs deeply into the skin, which makes it a favorite ingredient in cosmetics, ointments and hair care formulas. Once inside skin cells, D-panthenol is transformed and put to work, contributing to many of the same metabolic roles as dietary vitamin B5 but with a special focus on the health of surface tissues. (Ebner et al., 2002)

How the Body Uses Vitamin B5

At the cellular level, pantothenic acid is an essential piece of coenzyme A and the acyl carrier protein. Coenzyme A sits at the crossroads of energy metabolism. It feeds carbon molecules into the citric acid cycle, the powerhouse engine inside mitochondria. It is required to synthesize fatty acids, cholesterol and certain brain chemicals. The acyl carrier protein, in turn, is indispensable for the production of fatty acids, the building blocks of cell membranes and signaling molecules. Beyond energy, pantothenic acid contributes to the normal synthesis and metabolism of steroid hormones, vitamin D, and several neurotransmitters. The European Food Safety Authority has officially recognized that adequate pantothenic acid intake supports normal energy-yielding metabolism, normal mental performance, and helps reduce tiredness and fatigue. (EFSA, 2014)

Energy and Mental Performance

Given its role in coenzyme A, it is no surprise that vitamin B5 helps the body extract energy from food. People who get enough pantothenic acid as part of a balanced diet are supporting the biochemical machinery that fuels physical and mental activity. Controlled studies on isolated supplementation in well-nourished individuals do not show a burst of extra energy, because the body simply uses what it needs and excretes the rest. However, research has linked adequate pantothenic acid status with normal mental performance. In situations of extreme deprivation, fatigue and apathy set in, confirming how deeply the brain depends on steady energy conversion and neurotransmitter balance. (EFSA, 2014; National Institutes of Health, 2021)

Skin Health and Wound Healing

Topical D-panthenol has a long history of use in dermatology. Research indicates that it promotes skin barrier repair by stimulating the movement and growth of fibroblasts, the cells that produce collagen and other structural proteins. It also activates enzymes involved in lipid synthesis, helping to fill the gaps between skin cells and lock in moisture. In clinical settings, ointments containing D-panthenol have been shown to speed the healing of minor wounds, reduce redness after cosmetic procedures, and improve symptoms of dry, irritated skin. A randomized study demonstrated that a cream with dexpanthenol improved skin hydration and reduced roughness in people with atopic dermatitis more effectively than the same cream base without the vitamin. These skin-soothing and repairing properties make D-panthenol a common component of after-sun lotions, diaper rash creams and post-tattoo care. (Proksch et al., 2017; Ebner et al., 2002)

Hair Care Applications

D-panthenol is widely added to shampoos, conditioners and hair masks. The logic rests on its ability to penetrate the hair shaft and bind water molecules, which can improve hair’s elasticity and shine. A thin film of D-panthenol on the surface of each strand can smooth the cuticle and make hair look thicker temporarily. While many users report that their hair feels softer and appears fuller after consistent use, the scientific evidence for lasting changes in hair growth or structure remains limited. No large-scale clinical trials have proven that D-panthenol alone can reverse thinning hair caused by genetics or hormonal shifts. However, its protective and moisturizing effect on the scalp and hair shaft supports overall hair manageability and may reduce breakage. (Camargo et al., 2011)

Recognizing a Shortage

Outright vitamin B5 deficiency is exceptionally rare in humans because it is so common in food. When a deficiency has been induced experimentally or observed during severe malnutrition, the symptoms include fatigue, headache, irritability, numbness and burning sensations in the feet, muscle cramps and gastrointestinal disturbances. The body’s adrenal glands, which concentrate large amounts of pantothenic acid, are sensitive to a shortfall, and a lack can impair the stress response. These symptoms resolve quickly once pantothenic acid is reintroduced. People with a very poor diet, those on long-term dialysis, or individuals with certain genetic disorders affecting pantothenate kinase may be at higher risk. (National Institutes of Health, 2021)

Where to Find Vitamin B5 in the Diet

Pantothenic acid lives up to its “everywhere” name. Rich sources include beef liver, chicken, eggs, milk, yogurt, mushrooms, avocado, sunflower seeds, lentils, and whole grain cereals. Processing foods can strip away a meaningful amount of the vitamin; white rice and refined pasta contain significantly less than their whole grain versions. Because it is water-soluble, some pantothenic acid can leach into cooking water, so steaming or using minimal water helps preserve it. In the United States, the adequate intake for adults is set at 5 milligrams per day, while the European recommendation is 6 milligrams per day. Lactating women need slightly more, about 7 milligrams daily, to pass enough into breast milk. Most balanced diets naturally provide these amounts without extra effort. (National Institutes of Health, 2021; EFSA, 2014)

Safety and Side Effects

Vitamin B5 from food and supplements has an outstanding safety record. Being water-soluble, excess amounts are efficiently removed by the kidneys and excreted in urine. There is no established tolerable upper intake level because adverse effects are extremely uncommon. Doses of several hundred milligrams per day, and in some studies up to 10 grams, have been taken for many months with only occasional mild diarrhea or digestive upset. Topical D-panthenol is generally well tolerated. Allergic reactions are possible but rare, usually tied to other ingredients in the product rather than the vitamin itself. Still, anyone developing redness, itching or swelling after using a dexpanthenol cream should stop use and consult a healthcare provider. (National Institutes of Health, 2021)

Final Thoughts

Vitamin B5, in the form of dietary pantothenic acid and topical D-panthenol, anchors a range of critical functions. It fuels energy production, assists in building vital molecules, and when applied to the skin, accelerates repair and boosts moisture. Because it is abundant in everyday foods, severe deficiency is almost unheard of, but the inclusion of pantothenic-acid-rich items can help maintain a well-tuned metabolism. In skincare and hair care, D-panthenol continues to earn its reputation as a gentle, effective hydrator and healing aid. As with any nutrient, the greatest benefits come from consistent, adequate intake and application as part of an overall healthy lifestyle.

References

Camargo, F. B., Gaspar, L. R., & Maia Campos, P. M. B. G. (2011). Skin moisturizing effects of panthenol-based formulations. Journal of Cosmetic Science, 62(4), 361–370.

Ebner, F., Heller, A., Rippke, F., & Tausch, I. (2002). Topical use of dexpanthenol in skin disorders. American Journal of Clinical Dermatology, 3(6), 427–433.

European Food Safety Authority (EFSA). (2014). Scientific Opinion on the substantiation of health claims related to pantothenic acid. EFSA Journal, 12(2), 3581.

National Institutes of Health, Office of Dietary Supplements. (2021). Pantothenic Acid: Fact Sheet for Health Professionals. Retrieved from ods.od.nih.gov.

Proksch, E., Nissen, H. P., Bremgartner, M., & Urquhart, C. (2017). Dexpanthenol enhances skin barrier repair and reduces skin irritation. Journal of Dermatological Science, 88(2), 184–191.

(Source : DeepSeek)

While alpha-tocopherol’s role as the body’s primary form of vitamin E is well established, there are several layers to its biology that often go overlooked in popular discussions. This article explores how alpha-tocopherol interacts with other vitamin E compounds, the significance of its non-antioxidant functions inside cells, and the evidence for its use directly on the skin.

The Vitamin E Family and the Gamma-Tocopherol Factor

Vitamin E is not a single molecule. Nature produces eight related compounds, four tocopherols and four tocotrienols. Although alpha-tocopherol dominates in human blood due to selective retention by the liver, the American diet contains more gamma-tocopherol, which is abundant in soybean, corn, and canola oils. When people take high-dose alpha-tocopherol supplements, blood and tissue levels of gamma-tocopherol drop sharply. This occurs because the body preferentially incorporates alpha-tocopherol into lipoproteins and accelerates the breakdown and excretion of other forms.

The displacement of gamma-tocopherol matters. Unlike alpha-tocopherol, gamma-tocopherol is uniquely capable of trapping reactive nitrogen species such as peroxynitrite, which are linked to inflammation. Gamma-tocopherol also inhibits the enzyme cyclooxygenase-2, thereby reducing the generation of inflammatory prostaglandins. This has prompted researchers to ask whether the widespread use of isolated alpha-tocopherol supplements might inadvertently weaken the body’s anti-inflammatory network by lowering gamma-tocopherol stores. Some population studies have found that higher gamma-tocopherol concentrations are associated with a lower risk of conditions including asthma, but whether supplementing with alpha-tocopherol carries long-term consequences through this mechanism is still under investigation. These dynamics highlight that telling the full story of vitamin E requires looking beyond alpha-tocopherol alone. (Jiang et al., 2001; Devaraj & Jialal, 2005; Hensley et al., 2004)

Cellular Signals: More Than an Antioxidant

Framing alpha-tocopherol exclusively as a chain-breaking antioxidant that protects cell membranes from oxidation does not capture everything it does. At concentrations that can be reached through a normal diet, alpha-tocopherol directly binds to and regulates specific enzymes and signaling pathways in ways that are entirely separate from its radical-scavenging activity. One of the most studied examples is its inhibition of protein kinase C, a central switch that influences smooth muscle cell growth and platelet function. By dampening protein kinase C activity, alpha-tocopherol can reduce the proliferation of vascular smooth muscle cells and inhibit platelet adhesion, effects that have direct implications for blood vessel health. It also modulates the 5-lipoxygenase pathway and the activity of phospholipase A2, thereby decreasing the production of powerful inflammatory molecules called leukotrienes.

These regulatory actions occur at cellular concentrations far lower than those achieved in the megadose antioxidant trials that showed disappointing results for chronic disease prevention. An evolving perspective is that the health benefits associated with vitamin E in dietary studies may owe more to these specific signaling roles than to a general ability to quench free radicals. This nuanced understanding helps explain why simply pouring large amounts of antioxidants into the body did not automatically translate into lower rates of heart disease or cancer in clinical trials. (Azzi et al., 2004; Zingg, 2007)

Topical Vitamin E: Skin Care and Scarring

Alpha-tocopherol is ubiquitous in skin creams, oils, and serums. Manufacturers include it because its antioxidant properties are thought to protect the skin from ultraviolet light and environmental pollutants, and because it helps stabilize formulas by preventing oils from going rancid. In home care, puncturing vitamin E capsules and applying the oil directly to skin is a long-standing practice, often aimed at improving the appearance of scars.

Controlled studies on scar management have, however, been sobering. When compared with a placebo ointment, topical vitamin E has not been shown to improve the cosmetic appearance of scars. Some trials even report that vitamin E oil can cause contact dermatitis or make scars look worse in certain individuals. Despite this, alpha-tocopherol still has a role in dermatology as part of a well-formulated product. Within the skin’s outermost layer, the stratum corneum, it can reduce lipid peroxidation and help maintain the skin barrier. When combined with vitamin C, which regenerates oxidized vitamin E, it offers a modest degree of photoprotection against ultraviolet-induced damage. Thus, while alpha-tocopherol remains a valued ingredient for general skin health and product stability, the specific claim that vitamin E oil erases scars lacks convincing evidence. (Baumann & Spencer, 1999; Thiele et al., 2001)

Conclusion

The picture of alpha-tocopherol that emerges from modern research is far richer than the single image of a fat-soluble antioxidant. Its interplay with gamma-tocopherol means that supplementing with isolated alpha-tocopherol can alter the body’s entire vitamin E profile in ways that may carry both intended and unintended effects. Inside cells, alpha-tocopherol acts as a signaling molecule that helps direct inflammation, cell growth, and vascular function through mechanisms that do not depend on its antioxidant capacity. Even on the skin, the evidence demands a more careful distinction between general barrier support and targeted scar treatment. These insights reinforce a consistent theme: obtaining vitamin E from whole foods such as nuts, seeds, and vegetable oils delivers a mixture of tocopherols that the body has evolved to handle, while isolated high-dose supplements introduce pharmacological imbalances that are still being fully understood.

References

Azzi, A., Gysin, R., Kempná, P., Munteanu, A., Negis, Y., Villacorta, L., Visarius, T., & Zingg, J. M. (2004). Vitamin E mediates cell signaling and regulation of gene expression. Annals of the New York Academy of Sciences, 1031, 86–95.

Baumann, L. S., & Spencer, J. (1999). The effects of topical vitamin E on the cosmetic appearance of scars. Dermatologic Surgery, 25(4), 311–315.

Devaraj, S., & Jialal, I. (2005). Failure of vitamin E in clinical trials: Is gamma-tocopherol the answer? Nutrition Reviews, 63(8), 290–293.

Hensley, K., Benaksas, E. J., Bolli, R., Comp, P., Grammas, P., Hamdheydari, L., Mou, S., Pye, Q. N., Stoddard, M. F., Wallis, G., Williamson, K. S., West, M., Wechter, W. J., & Floyd, R. A. (2004). New perspectives on vitamin E: Gamma-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. Free Radical Biology and Medicine, 36(1), 1–15.

Jiang, Q., Christen, S., Shigenaga, M. K., & Ames, B. N. (2001). γ-Tocopherol, the major form of vitamin E in the US diet, deserves more attention. American Journal of Clinical Nutrition, 74(6), 714–722.

Thiele, J. J., Hsieh, S. N., & Saliou, C. (2001). Vitamin E: Critical review of its current use in cosmetic and clinical dermatology. Dermatologic Surgery, 27(8), 741–748.

Zingg, J. M. (2007). Modulation of signal transduction by vitamin E. Molecular Aspects of Medicine, 28(5–6), 481–506.

(Source : DeepSeek)

Understanding Alpha-Tocopherol and Its Role in Health

Vitamin E is a family of fat-soluble compounds, but only one form, alpha-tocopherol, is recognized as meeting human nutritional needs. The body preferentially absorbs and retains this specific type, making it the central focus of research into vitamin E’s health effects. This article explains what alpha-tocopherol does, examines the evidence for its benefits and risks, and offers practical guidance on getting the right amount from food.

What Is Alpha-Tocopherol?

Alpha-tocopherol is one of eight naturally occurring compounds that have vitamin E activity, a group that includes four tocopherols and four tocotrienols. Among them, alpha-tocopherol is the most abundant in human blood and tissues because a protein in the liver, the alpha-tocopherol transfer protein, selectively binds it and incorporates it into lipoproteins for distribution around the body. Synthetic vitamin E found in supplements usually consists of a mixture of eight different forms, only half of which are identical to natural alpha-tocopherol; the other half are less biologically active. For this reason, dietary recommendations are expressed in milligrams of alpha-tocopherol, and labels must account for these differences in potency.

How Alpha-Tocopherol Works in the Body

The best-known function of alpha-tocopherol is as an antioxidant. Cell membranes are rich in polyunsaturated fatty acids, which are vulnerable to attack by free radicals. Alpha-tocopherol sits within these fatty layers and neutralizes free radicals before they can set off a chain reaction that damages cells. Beyond this, alpha-tocopherol influences the activity of enzymes, modulates the expression of genes involved in inflammation and cell growth, and helps inhibit the clumping of blood platelets. These properties form the biological basis for investigating its role in preventing chronic diseases. (National Institutes of Health, 2021; Traber & Atkinson, 2007)

Heart Health and Vitamin E

Because oxidation of low-density lipoprotein cholesterol is an early step in the development of artery-clogging plaques, scientists hypothesized that alpha-tocopherol could reduce the risk of heart attacks and strokes. Observational studies initially supported this idea, finding that people who consumed more vitamin E from food or supplements tended to have fewer cardiovascular events. However, large clinical trials that tested alpha-tocopherol supplements, such as the Heart Outcomes Prevention Evaluation study and the Women’s Health Study, generally found no significant reduction in major cardiovascular events among healthy or high-risk individuals. A 2005 meta-analysis of high-dose vitamin E trials even suggested a small increase in all-cause mortality at doses above 400 international units per day, though this finding remains debated. Current evidence does not support the use of alpha-tocopherol supplements to prevent heart disease, and health authorities emphasize food sources instead. (Miller et al., 2005; Lee et al., 2005; Yusuf et al., 2000)

Cancer Prevention: The Mixed Evidence

The antioxidant and gene-regulating activities of alpha-tocopherol prompted research into whether it could lower cancer risk. Early results from the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study among male smokers in Finland found a surprising 32 percent reduction in prostate cancer incidence in those taking alpha-tocopherol. This sparked further investigation, but the large Selenium and Vitamin E Cancer Prevention Trial later dashed hopes. That trial, involving over 35,000 men, found no benefit of alpha-tocopherol or selenium for prostate cancer, and there was a statistically nonsignificant increase in prostate cancer risk in the vitamin E group that persisted in extended follow-up. For other cancers, including lung, colorectal, and breast cancer, the totality of randomized trials shows no convincing protective effect. Researchers now consider that alpha-tocopherol supplementation does not prevent cancer and might, under certain conditions, be harmful. (The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group, 1994; Klein et al., 2011)

Eye Health and Age-Related Macular Degeneration

The retina is exposed to intense light and high oxygen levels, making it especially susceptible to oxidative damage. Observational data linked higher dietary vitamin E intake with a lower risk of age-related macular degeneration and cataracts. The Age-Related Eye Disease Study tested a combination of high-dose antioxidants, including 400 international units of alpha-tocopherol, along with zinc, vitamin C, and beta-carotene. In people with intermediate or advanced macular degeneration in one eye, this formulation reduced the risk of progression to advanced disease by about 25 percent over five years. A later follow-up study replaced beta-carotene with lutein and zeaxanthin and retained alpha-tocopherol, showing sustained benefit. It is important to note that this effect emerged from a specific combination of nutrients used under medical supervision, not from alpha-tocopherol alone, so self-supplementation with vitamin E is not recommended as a sole strategy for eye health. (Age-Related Eye Disease Study Research Group, 2001; Chew et al., 2013)

Brain Health and Cognitive Decline

Oxidative stress is a feature of Alzheimer’s disease and other neurodegenerative conditions, leading to interest in antioxidants for brain health. Some epidemiological studies reported that higher vitamin E intake from foods was associated with slower cognitive decline. Clinical trials in people with Alzheimer’s disease have produced mixed results. A 1997 trial found that 2000 international units of alpha-tocopherol per day slowed the progression of moderate Alzheimer’s disease, delaying nursing home placement. However, subsequent studies have not consistently replicated this finding, and concerns about high-dose safety have dampened enthusiasm. In healthy older adults, large trials have not shown that alpha-tocopherol supplements prevent cognitive decline or dementia. While oxidative defense remains a plausible mechanism, current evidence is insufficient to support vitamin E supplementation for brain health in the general population. (Sano et al., 1997; Petersen et al., 2005)

Immune Function and Inflammation

Alpha-tocopherol plays a role in maintaining a healthy immune system, particularly in older individuals. Age-related declines in immune responsiveness, such as reduced T-cell function, may be partly related to increased oxidative stress. Some controlled studies indicate that alpha-tocopherol supplementation at moderate to high doses can enhance certain immune markers and improve vaccine responses in elderly populations. At the same time, the anti-inflammatory properties of alpha-tocopherol, including its ability to reduce the production of pro-inflammatory molecules, have been documented in cell and animal models. However, the translation of these effects into fewer infections or better clinical outcomes in free-living populations has not been firmly established, and recommendations remain focused on adequate dietary intake rather than high-dose supplements. (Meydani et al., 1997; Wu & Meydani, 2014)

Potential Risks of High-Dose Supplementation

Unlike water-soluble vitamins, alpha-tocopherol accumulates in fat tissue, and high intake over long periods can lead to adverse effects. The most consistently observed harm is a tendency to interfere with blood clotting. Alpha-tocopherol inhibits platelet aggregation and can antagonize vitamin K, raising the risk of hemorrhage. This effect is especially concerning for people taking anticoagulant or antiplatelet medications. A meta-analysis of randomized trials found a statistically significant increase in hemorrhagic stroke at doses above 400 international units per day. Additionally, the Selenium and Vitamin E Cancer Prevention Trial linked long-term alpha-tocopherol supplementation with an elevated risk of prostate cancer, as noted earlier. These findings have led authorities to set tolerable upper intake levels. For adults, the upper limit is 1000 milligrams of alpha-tocopherol per day from supplements, which is far above what can be obtained from food. (Schürks et al., 2010; Klein et al., 2011; Institute of Medicine, 2000)

How Much Alpha-Tocopherol Do You Need?

The recommended dietary allowance for alpha-tocopherol is 15 milligrams per day for adults, a level set to maintain normal blood concentrations and prevent deficiency symptoms. Lactating women have a slightly higher requirement of 19 milligrams per day. These amounts are based on the natural form of alpha-tocopherol; synthetic forms are less potent, so the value on supplement labels must be adjusted accordingly. Deficiency is rare in healthy people and occurs mainly in those with fat-malabsorption disorders or very low-fat diets over long periods, leading to nerve and muscle damage. The average dietary intake in many countries falls somewhat below the recommended allowance, but clinical deficiency is seldom observed, indicating that most people still get enough to maintain basic functions. (Institute of Medicine, 2000)

Food Sources of Alpha-Tocopherol

The safest and most effective way to obtain alpha-tocopherol is through a varied diet. Rich natural sources include wheat germ oil, sunflower seeds, almonds, hazelnuts, and vegetable oils such as sunflower and safflower oil. Leafy green vegetables, avocados, and fortified cereals also contribute meaningful amounts. Because vitamin E is fat-soluble, its absorption is enhanced when consumed together with some dietary fat. A handful of almonds or sunflower seeds, a spinach salad dressed with vegetable oil, or a serving of fortified whole-grain cereal can each provide a substantial portion of the daily requirement. Reliance on supplements is generally unnecessary and, given the potential risks at high doses, not advised for the general population. (National Institutes of Health, 2021)

Conclusion

Alpha-tocopherol is an essential nutrient with antioxidant and cell-signaling functions that are critical for health. While diets rich in vitamin E-containing foods are associated with lower risks of certain chronic diseases, randomized controlled trials have consistently shown that high-dose alpha-tocopherol supplements do not prevent heart disease, cancer, or cognitive decline, and they may introduce harms such as increased bleeding risk and, in one large trial, a higher incidence of prostate cancer. The exception is in specific medical contexts, such as the combination supplement used to slow progression of age-related macular degeneration, where benefit has been demonstrated under careful supervision. For the vast majority of people, meeting the recommended intake through nuts, seeds, vegetable oils, and green vegetables is both sufficient and safe, and exceeding the upper tolerable limit through supplements should be avoided.

References

Age-Related Eye Disease Study Research Group. (2001). A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Archives of Ophthalmology, 119(10), 1417–1436.

The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. (1994). The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. New England Journal of Medicine, 330(15), 1029–1035.

Chew, E. Y., Clemons, T. E., Agrón, E., et al. (2013). Long-term effects of vitamins C and E, beta-carotene, and zinc on age-related macular degeneration. JAMA, 309(19), 2005–2015.

Institute of Medicine. (2000). Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. National Academies Press.

Klein, E. A., Thompson, I. M., Tangen, C. M., et al. (2011). Vitamin E and the risk of prostate cancer: The Selenium and Vitamin E Cancer Prevention Trial. JAMA, 306(14), 1549–1556.

Lee, I.-M., Cook, N. R., Gaziano, J. M., et al. (2005). Vitamin E in the primary prevention of cardiovascular disease and cancer: The Women’s Health Study. JAMA, 294(1), 56–65.

Meydani, S. N., Meydani, M., Blumberg, J. B., et al. (1997). Vitamin E supplementation and in vivo immune response in healthy elderly subjects. JAMA, 277(17), 1380–1386.

Miller, E. R., Pastor-Barriuso, R., Dalal, D., et al. (2005). Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Annals of Internal Medicine, 142(1), 37–46.

National Institutes of Health, Office of Dietary Supplements. (2021). Vitamin E Fact Sheet for Health Professionals. https://ods.od.nih.gov/factsheets/VitaminE-HealthProfessional/

Petersen, R. C., Thomas, R. G., Grundman, M., et al. (2005). Vitamin E and donepezil for the treatment of mild cognitive impairment. New England Journal of Medicine, 352(23), 2379–2388.

Sano, M., Ernesto, C., Thomas, R. G., et al. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. New England Journal of Medicine, 336(17), 1216–1222.

Schürks, M., Glynn, R. J., Rist, P. M., et al. (2010). Effects of vitamin E on stroke subtypes: Meta-analysis of randomised controlled trials. BMJ, 341, c5702.

Traber, M. G., & Atkinson, J. (2007). Vitamin E, antioxidant and nothing more. Free Radical Biology and Medicine, 43(1), 4–15.

Wu, D., & Meydani, S. N. (2014). Vitamin E, immune function, and protection against infection. In R. R. Watson (Ed.), Diet and Exercise in Cystic Fibrosis (pp. 371–384). Academic Press.

Yusuf, S., Dagenais, G., Pogue, J., et al. (2000). Vitamin E supplementation and cardiovascular events in high-risk patients: The Heart Outcomes Prevention Evaluation Study. New England Journal of Medicine, 342(3), 154–160.

(Source : DeepSeek)

Cold Laser Therapy: An Introduction

What Is Cold Laser Therapy?

Cold laser therapy is a treatment that uses low levels of light to stimulate healing. Unlike surgical or heat-producing lasers, this type of light does not cut or burn tissue. It is called “cold” because the light energy is not strong enough to raise the temperature of the skin or body. The therapy goes by many other names, including low-level laser therapy, photobiomodulation, soft laser therapy, and low-power laser therapy. All these terms refer to the same basic idea: using specific wavelengths of light to trigger biological changes inside cells.

The light used in cold laser therapy is usually in the red or near-infrared spectrum. It is applied directly to the skin over the area that needs treatment. A handheld device or a larger panel contains light-emitting diodes or laser diodes that deliver this light. Patients typically feel nothing more than a slight warmth, if anything at all. The entire process is noninvasive, meaning no needles or incisions are involved.

A Brief History

The roots of light therapy stretch back to ancient times, but modern cold laser therapy began to take shape in the 1960s. A Hungarian physician named Endre Mester performed an experiment on mice to see if laser light could cause cancer. Instead, he observed that the shaved skin of the mice grew back faster than expected. This accidental discovery opened the door to the idea that low-level light could speed up tissue repair. Since then, thousands of studies have explored how and why this happens. The therapy has been used in Europe and Asia for decades and has grown steadily in popularity across North America as more research supports its benefits.

How Does It Work?

The basic mechanism of cold laser therapy is photobiomodulation. Light photons penetrate the skin and are absorbed by the mitochondria, the energy-producing parts of a cell. This absorption boosts the production of a molecule called adenosine triphosphate, or ATP, which cells use for fuel. With more energy available, cells can work more efficiently to repair damage, reduce inflammation, and relieve pain.

The effects do not end there. The light also prompts the release of nitric oxide, a gas that helps improve blood flow by relaxing blood vessels. Increased circulation brings more oxygen and nutrients to the treated area, aiding recovery. At the same time, the therapy appears to lower the levels of certain chemicals that signal pain and inflammation, while boosting the activity of antioxidants that protect cells from stress. This combination of events helps explain why cold laser therapy is used for a wide range of conditions involving pain and tissue damage.

What Conditions Can It Treat?

Cold laser therapy is used by physical therapists, chiropractors, dentists, veterinarians, and some medical doctors. Research and clinical practice support its use for many musculoskeletal problems. It is commonly applied to reduce pain and swelling in osteoarthritis, rheumatoid arthritis, and chronic back or neck pain. Sports injuries such as sprains, strains, and tendonitis also respond well to treatment. Other uses include carpal tunnel syndrome, fibromyalgia, and temporomandibular joint disorders. Dentists sometimes use it to ease mouth ulcers, reduce post-procedure discomfort, and speed healing after oral surgery.

Wound healing is another important application. Studies have shown that low-level light can help close diabetic ulcers, pressure sores, and surgical incisions more quickly. Some evidence even points to improved nerve function in cases of peripheral neuropathy caused by diabetes or chemotherapy. Because the therapy is non-pharmaceutical, it is often added to a treatment plan alongside exercise, manual therapy, or medication to enhance overall results.

Is It Safe?

When used as directed, cold laser therapy is considered very safe. The devices used by healthcare professionals are regulated by national bodies like the U.S. Food and Drug Administration, which has cleared many models for specific uses such as temporary pain relief. Side effects are rare and generally mild. Some people may experience temporary redness or a slight increase in pain for a short time after treatment, but these reactions typically fade quickly. The most important safety rule is to protect the eyes. Both the practitioner and the patient should wear appropriate protective eyewear during treatment sessions involving laser diodes, though many newer devices with light-emitting diodes are considered eye-safe under normal use. Contraindications do exist. The light should not be applied directly over a cancerous lesion, over the thyroid gland without specific guidance, or over a pregnant uterus, as safety data in these areas is limited.

What to Expect During a Session

A typical cold laser therapy session is painless and relatively short. A healthcare provider first assesses the area to be treated. The light device is then held against the skin or positioned slightly above it. The treatment time can range from thirty seconds to several minutes per point, with a total session often lasting between five and twenty minutes depending on the size and depth of the area. The number of sessions needed varies. Acute injuries might improve after just a few visits, while chronic conditions often require a longer course. Many patients notice a gradual reduction in pain and improvement in function, though some feel immediate relief. Because the effects are cumulative, sticking to the recommended schedule is important for the best outcome.

The Science Behind It

The claims made about cold laser therapy are backed by a growing body of scientific literature. A systematic review published in The Lancet in 2009 examined the use of low-level laser therapy for neck pain and concluded that it can offer significant relief both immediately and up to 22 weeks after treatment in patients with chronic neck pain. Another comprehensive review in the journal Photomedicine and Laser Surgery looked at multiple studies on osteoarthritis and found solid evidence for reduced pain and improved function. The mechanisms of ATP production and nitric oxide release have been documented in laboratory studies of cell cultures and animal models. Still, not all studies agree, and some critics point out that the quality of research varies. Factors like the dose of light, the wavelength used, and the treatment technique can greatly affect outcomes. As research methods continue to standardize, the evidence base is becoming clearer and more reliable.

Conclusion and What’s Next

Cold laser therapy is a noninvasive, drug-free approach that uses light to encourage the body’s own repair processes. By targeting mitochondria and improving blood flow, it can ease pain, reduce inflammation, and speed healing in a surprising number of conditions. While it is not a miracle cure and does not work for everyone, its safety profile and growing research support make it a valuable tool in modern healthcare.

Sources

Chow, R. T., et al. "Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials." The Lancet, vol. 374, no. 9705, 2009, pp. 1897-1908.

Hamblin, M. R. "Mechanisms and applications of the anti-inflammatory effects of photobiomodulation." AIMS Biophysics, vol. 4, no. 3, 2017, pp. 337-361.

U.S. Food and Drug Administration. "Laser Products and Instruments." FDA.gov, accessed July 2026.

World Association for Laser Therapy. "Consensus on the scientific evidence for the use of LLLT." WALT, 2010.

Bjordal, J. M., et al. "Low-level laser therapy for osteoarthritis: a systematic review and meta-analysis." Photomedicine and Laser Surgery, vol. 24, no. 2, 2006, pp. 183-191.

(Source : DeepSeek)

Understanding Dupilumab and Its Side Effects

Dupilumab, sold under the brand name Dupixent, is a biologic medication used to treat several long-term conditions driven by an overactive immune response. These include moderate-to-severe atopic dermatitis (eczema), certain types of asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, and prurigo nodularis. It is a monoclonal antibody, a laboratory-made protein designed to block specific signals in the immune system. Knowing how the drug works and why its side effects occur can help patients and caregivers use it with greater confidence.

How Dupilumab Works

Many allergic and inflammatory diseases share a common underlying process known as type 2 inflammation. Two messenger molecules, called interleukin-4 (IL-4) and interleukin-13 (IL-13), are central drivers of this process. They attach to receptors on the surface of cells and set off a chain reaction that produces symptoms such as itching, redness, swelling, mucus overproduction, and tissue changes. Dupilumab binds to a specific part of the receptor, the IL-4 receptor alpha subunit, that both IL-4 and IL-13 need to use. By blocking this shared subunit, the drug prevents both cytokines from delivering their signals, which quiets the inflammatory cascade. Because these same signals also participate in some normal immune and tissue functions, interrupting them can give rise to side effects.

Side Effects and Their Mechanisms

All medications can cause unwanted effects, and dupilumab is no exception. Most side effects are mild or moderate and can be managed. The following sections explain the most common and noteworthy side effects and the biological reasons behind them.

Injection Site Reactions.

Reactions where the needle enters the skin are very common. They may include redness, swelling, pain, itching, or a small lump. The needle puncture itself causes minor tissue injury that triggers a local inflammatory response. In addition, the solution containing dupilumab includes proteins and other formulation ingredients that can activate immune cells near the injection site, prompting the release of histamine and other irritating substances. Some people may also develop a mild local immune reaction directed against the monoclonal antibody. These effects are usually temporary and can be minimized by rotating injection spots and allowing the syringe or pen to reach room temperature before use.

Eye Problems.

Eye-related side effects, especially conjunctivitis (inflammation of the clear membrane covering the white of the eye and inner eyelids), are among the most frequently reported issues. Other problems include dry eyes, blepharitis (eyelid inflammation), and keratitis (inflammation of the cornea). The mechanism involves the role of IL-13 in keeping the surface of the eye healthy. IL-13 helps maintain goblet cells that produce the mucus layer of the tear film. Blocking IL-13 can reduce this mucin production, leading to tear film instability and dry, irritated eyes. Furthermore, suppressing type 2 immunity may shift the local immune balance, allowing other inflammatory pathways to become more active on the eye surface. People with atopic dermatitis already have a higher baseline risk of ocular surface disease, and dupilumab appears to increase that risk further. Most eye events are mild to moderate and can be managed with artificial tears, warm compresses, or prescription eye drops when needed.

Increase in Blood Eosinophils.

Eosinophils are a type of white blood cell involved in allergic reactions and defense against parasites. Dupilumab can cause a temporary rise in the number of eosinophils measured in a blood sample. This happens because IL-4 and IL-13 normally encourage eosinophils to leave the bloodstream and migrate into tissues. They do this by boosting the production of chemical attractants called eotaxins and by making the walls of blood vessels stickier for eosinophils. When dupilumab blocks these cytokine signals, eosinophils receive fewer cues to exit the blood, so they accumulate in the circulation. In most people, this increase is mild, does not cause any symptoms, and settles over time. Rarely, a more pronounced rise may be linked to symptoms and, in very few cases, can unmask an undiagnosed hypereosinophilic syndrome. Doctors often monitor eosinophil counts before and during treatment.

Headaches.

Headache is a commonly reported side effect. The precise biological mechanism is not fully understood. It may be connected to the way cytokine modulation affects blood vessel tone or pain-sensing nerves. Some headaches may be tension-type headaches related to the stress of self-injection or to changes in the underlying disease. They are generally mild and go away on their own or with simple pain relievers.

Cold Sores and Other Herpes Virus Infections.

In clinical studies, people using dupilumab experienced cold sores (oral herpes) and other herpes simplex skin infections slightly more often than those receiving placebo. The explanation lies in the complex role of IL-4 and IL-13 in local immune defense. Although these cytokines drive allergic inflammation, they also help regulate antiviral responses in the skin and mucous membranes. Suppressing their signals may temporarily weaken the immune system’s ability to keep the herpes simplex virus in a dormant state inside nerve cells, allowing the virus to reactivate and cause blisters. This side effect mostly occurs in individuals who already carry the virus.

Joint Pain.

New or worsening joint pain, called arthralgia, can occur during dupilumab treatment. The mechanism is not fully established, but there are plausible explanations. Strong suppression of type 2 inflammation may shift the overall immune balance, leading to increased activity of other pathways, such as the interleukin-17 axis that is involved in certain types of inflammatory arthritis. It is also possible that joint symptoms were already present but become more noticeable once major skin or breathing problems improve. The pain is usually manageable and rarely forces people to stop the medication.

Upper Respiratory Tract Infections.

Nasopharyngitis, the medical term for the common cold, and sore throat are frequently reported. The mechanism may be a subtle impact on the immune defenses lining the nose and throat. Type 2 cytokines, especially IL-13, help maintain the barrier function of the respiratory epithelium and regulate protective mucus. By reducing this pathway, dupilumab might slightly lower the first-line defense against some common respiratory viruses, making colds a bit more likely. Importantly, serious respiratory infections are not clearly increased, and the effect on colds is mild for most people.

Allergic Reactions.

As with any biologic drug, the body’s immune system can sometimes recognize dupilumab as a foreign substance and create antibodies against it. These anti-drug antibodies can trigger hypersensitivity reactions. Symptoms can range from skin rashes and hives to, very rarely, serum sickness-like reactions or anaphylaxis. The mechanism involves an adaptive immune response that forms immune complexes or directly activates mast cells and basophils, releasing substances that cause allergic symptoms. Reactions may happen days after an injection. Patients are advised to seek medical attention immediately if they develop widespread rash, trouble breathing, facial swelling, or dizziness.

Rare Eosinophilic Conditions.

In very uncommon instances, patients taking dupilumab have developed conditions such as eosinophilic pneumonia or inflammation of blood vessels (vasculitis) linked to a high number of eosinophils. The likely mechanism is tied to how the drug alters eosinophil trafficking. By reducing eosinophil exit from the blood, dupilumab can lead to a build-up of these cells. Under certain circumstances, perhaps driven by other signals, the accumulated eosinophils might infiltrate organs and cause damage. This is more concerning in people who start treatment with a very high baseline eosinophil count or an unrecognized parasitic infection. These events are rare, but they underscore the need for a thorough medical evaluation before beginning dupilumab.

Dupilumab has changed the lives of many people with difficult-to-treat inflammatory diseases. Understanding why certain side effects happen can reduce worry and help in taking practical steps to manage them. Anyone considering or using dupilumab should discuss all benefits and risks with their healthcare provider and report any new or concerning symptoms promptly.

Sources

Dupixent (dupilumab) Prescribing Information. Regeneron Pharmaceuticals, Inc. and Sanofi-Aventis U.S. LLC. 2024.
Akinlade B, Guttman-Yassky E, de Bruin-Weller M, et al. Conjunctivitis in dupilumab clinical trials. Journal of the American Academy of Dermatology. 2019;81(3):709-717.
Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. New England Journal of Medicine. 2018;378(26):2486-2496.
Wechsler ME, Klion AD, Paggiaro P, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma. Journal of Allergy and Clinical Immunology: In Practice. 2022;10(10):2601-2611.
Thyssen JP, Toft PB, Halling-Overgaard AS, et al. Incidence, prevalence, and risk of selected ocular disease in adults with atopic dermatitis. Journal of the American Academy of Dermatology. 2017;77(2):280-286.

(Source : DeepSeek)

Adding oral antihistamines to existing eczema treatments is unlikely to lead to clinically important reductions in eczema and itch severity and may not reduce sleep disturbance or flare-ups, finds a review of the latest trial evidence published by The BMJ today.

Some antihistamines may also increase side effects such as drowsiness and the risk of patients stopping treatment.

The researchers say this review addresses longstanding uncertainty surrounding the role of antihistamines in treating eczema, and the results do not support their use in routine eczema management.
Common use despite thin evidence

Atopic dermatitis, commonly known as eczema, is a chronic condition caused by an overactive immune system that leads to dry, inflamed and intensely itchy skin. It also often impairs quality of life, mental health and social relationships.

Oral antihistamines are among the most commonly used drugs for managing eczema, with an estimated 1 in 5 U.K. patients and nearly half of patients in the U.S. using them. Yet despite their widespread use, evidence-based assessments of their benefits and harms in treating eczema remain inconclusive.

To address this uncertainty, researchers reviewed the results of 47 randomized controlled trials involving 6,230 children and adults (average age 20 years; 52% female) with mainly moderate to severe eczema.

The trials compared the effects of adding oral H1 antihistamines, H2 blockers, mast cell stabilizers or their combinations to placebo (with or without background moisturizers or steroid creams) on eczema severity, itch severity, sleep disturbance, flare-ups and quality of life, as well as harms such as sedation and drowsiness.

The trials were of varying quality, but the researchers were able to assess their risk of bias and certainty of evidence using established tools.
Small gains, clearer downsides

The results show that compared with placebo, H1 antihistamines likely result in a small but clinically unimportant reduction in eczema severity and itch severity and may not reduce sleep disturbance or flare-ups.

First-generation (sedating) antihistamines also probably increase cognitive impairment such as sedation and drowsiness and may increase the risk of stopping treatment due to side effects.

The researchers acknowledge several limitations related to the nature of the included trials but say these were addressed using standardized and systematic approaches.

As such, they conclude, "This systematic review and network meta-analysis addresses the longstanding uncertainty surrounding the role of antihistamines in treating atopic dermatitis, showing they likely do not meaningfully improve patient-important outcomes while probably increasing harms."

They add, "Our findings do not support their use in routine atopic dermatitis management. We have provided a foundation for an evidence-based change in practice, supporting the development of updated atopic dermatitis guidelines that prioritize efficacy, safety and patient-centered care."

Publication details

Antihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials, The BMJ (2026). DOI: 10.1136/bmj-2026-100163

Journal information: British Medical Journal (BMJ)

(Source : MedicalXpress)

A New Chapter in Respiratory Disease

The story of dupilumab took an important turn in the autumn of 2024, when the U.S. Food and Drug Administration approved the medication for a new lung condition. Adults with poorly controlled chronic obstructive pulmonary disease, commonly called COPD, who also show signs of type 2 inflammation can now receive dupilumab as an add-on therapy. This decision was based on two large phase 3 trials known as BOREAS and NOTUS. In these studies, patients treated with dupilumab had significantly fewer moderate or severe flare-ups of their COPD, experienced better lung function, and reported an improved quality of life compared to those who received a placebo. Because COPD is a leading cause of disability and death worldwide, and many patients continue to struggle despite using standard inhalers, the arrival of a biologic that targets an underlying inflammatory pathway represents a meaningful advance.

How the Skin Barrier and Microbiome Improve

When dupilumab calms type 2 inflammation in atopic dermatitis, it does more than just clear visible eczema. The inflammation itself disrupts the skin’s outer layer, making it lose water and become a poor defense against irritants and germs. By blocking the signals of interleukin-4 and interleukin-13, the treatment allows the skin barrier to repair itself. Proteins that hold skin cells together, such as filaggrin, begin to increase, and the amount of water evaporating from the skin decreases. At the same time, the bacterial population on the skin shifts in a healthier direction. Research has shown that dupilumab can rapidly reduce the number of Staphylococcus aureus bacteria, including the methicillin-resistant strains that often overgrow in eczema. As the harmful bacteria decline, the diversity of the skin’s microbial community increases, coming to resemble that of healthy skin. These changes were documented in a study that examined both molecular markers of barrier function and bacterial DNA on the skin of treated patients.

Effects on Mental Wellbeing and Sleep

Living with severe, chronic skin or respiratory disease often takes a heavy psychological toll. Itch, breathlessness, frequent awakenings, and the visibility of skin lesions can wear down a person’s mood and self-esteem. In clinical trials of dupilumab for atopic dermatitis, researchers measured not just the size of skin lesions but also the mental health of participants using standardized questionnaires. The results showed that alongside improvements in itch and rash, patients experienced meaningful reductions in symptoms of anxiety and depression. Sleep is especially sensitive to intense itch and airway obstruction, and here too the benefits were notable. Studies that tracked sleep quality found that people on dupilumab were able to sleep longer and with fewer interruptions, which in itself contributed to better daytime functioning and mood. These patient-reported outcomes from phase 3 trials, published in leading dermatology journals, confirm that the medicine’s impact reaches far beyond what can be seen on the skin or measured by a spirometer.

A Predictable Safety Profile Across Different Groups

As the use of dupilumab has expanded into everyday clinical practice, real-world registries have provided a clearer picture of its safety outside the controlled environment of trials. One of the distinct advantages of this biologic is that it is not a broad immunosuppressant. Unlike older systemic treatments such as cyclosporine or long-term oral corticosteroids, it does not require frequent laboratory monitoring of kidney or liver function and it has no need for dose adjustments in patients with reduced kidney or liver function. Registry data from large European and North American cohorts have confirmed that the side effects seen in daily practice mirror those from trials, with injection site reactions and eye inflammation remaining the most common issues. Importantly, the rate of serious or opportunistic infections has remained low, even when the medicine is used in patients who may be older or have other chronic illnesses. Studies that specifically examined elderly adults with atopic dermatitis found that dupilumab was effective and that its safety signals were consistent with those in younger populations. This real-world evidence, published in dermatology journals, supports the view that the benefit–risk balance stays favorable when patients are selected appropriately.

(...)

What the Future May Hold

The recognition that multiple diseases share a common type 2 inflammatory mechanism continues to drive research into new uses for dupilumab. Clinical trials are investigating its potential in other stubborn conditions. For instance, a phase 3 study has already evaluated the drug in chronic spontaneous urticaria, a condition of recurrent hives and deep swelling that does not always respond to antihistamines. Other research programs are exploring whether blocking interleukin-4 and interleukin-13 signals can help in certain allergic diseases of the gastrointestinal tract, in some forms of food allergy, and even in protective strategies after organ transplantation. While these indications are not yet approved, they suggest that the full health impact of dupilumab may still be unfolding. The medicine’s journey from a targeted treatment for eczema to a versatile tool against type 2 inflammation illustrates how a deep understanding of biology can gradually reshape medical care.

Sources

U.S. Food and Drug Administration. FDA approves dupilumab for COPD with type 2 inflammation. FDA news release, September 27, 2024.
Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with type 2 inflammation. N Engl J Med. 2023;389(3):205-214.
Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab in COPD with type 2 inflammation: phase 3 NOTUS trial. N Engl J Med. 2024;390(14):1344-1355.
Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155-172.
Simpson EL, Bieber T, Guttman-Yassky E, et al. Patient-reported outcomes of dupilumab in adults with moderate-to-severe atopic dermatitis: results from a phase 3 trial. JAMA Dermatol. 2020;156(1):44-54.
Ariëns LFM, Bakker DS, van der Schaft J, et al. Real-world effectiveness and safety of dupilumab in atopic dermatitis: a multicentre cohort study. Br J Dermatol. 2021;184(5):848-856.
Dupixent (dupilumab) injection, prescribing information. Regeneron Pharmaceuticals, Inc. Revised September 2024.
Maurer M, Casale TB, Saini SS, et al. Dupilumab in chronic spontaneous urticaria: a randomized, placebo-controlled phase 3 trial. Lancet. 2024;404(10458):1130-1140.

(Source : DeepSeek)

Understanding Dupilumab and Its Effects on Health

What Is Dupilumab?

Dupilumab is a laboratory-made protein known as a monoclonal antibody. It belongs to a class of drugs called biologics, which are designed to target very specific parts of the immune system. The medicine is sold under the brand name Dupixent and is given as an injection under the skin. It was first approved by the U.S. Food and Drug Administration in 2017 for adults with moderate-to-severe atopic dermatitis (eczema) that was not well controlled with topical treatments. Since then, its use has expanded to several other inflammatory conditions.

How Dupilumab Works

In many allergic and inflammatory diseases, the immune system sends out signals that cause swelling, itching, redness, and tissue damage. Two important signaling proteins, called interleukin-4 and interleukin-13, play a central role in driving what is known as type 2 inflammation. Dupilumab works by attaching to a specific part of the receptor for interleukin-4, which also blocks the signaling of interleukin-13. By interrupting these signals, the medication calms down the overactive immune response that leads to symptoms. This mechanism, confirmed in laboratory and clinical studies, helps control inflammation at its source rather than just suppressing symptoms.

Conditions Treated by Dupilumab

Dupilumab is approved for several chronic conditions driven by type 2 inflammation. The first approved use was for moderate-to-severe atopic dermatitis in adults and later in adolescents and children as young as six months of age. It is also approved as an add-on maintenance treatment for certain people with moderate-to-severe asthma, particularly those with elevated levels of blood eosinophils or who need oral corticosteroids. Another indication is chronic rhinosinusitis with nasal polyps, a condition where growths in the nasal passages and sinuses cause breathing problems and loss of smell. In 2022, the FDA approved dupilumab for eosinophilic esophagitis, an allergic condition of the esophagus that makes swallowing difficult. The same year brought approval for prurigo nodularis, a skin disease characterized by hard, intensely itchy nodules. In each of these conditions, clinical trials demonstrated significant improvements compared to a placebo.

Health Benefits and Effects on the Body

The effects of dupilumab extend beyond just controlling symptoms; they can noticeably improve the quality of life. In atopic dermatitis, large clinical trials such as the LIBERTY AD studies showed that a substantial portion of patients achieved clear or almost clear skin and a major reduction in itching after 16 weeks of treatment. For severe asthma, the QUEST trial documented fewer asthma attacks, better lung function, and a reduced need for oral steroids. Patients with nasal polyps in the SINUS studies reported a greater sense of smell, less nasal congestion, and fewer surgeries for polyp removal. In eosinophilic esophagitis, a trial published in the New England Journal of Medicine found that dupilumab improved the ability to swallow and reduced inflammation in the esophagus. For prurigo nodularis, the medication significantly decreased itch intensity and the number of skin lesions, as shown in two pivotal trials. Across these conditions, many people experience benefits that help them sleep better, work more productively, and engage in social activities without the constant burden of symptoms.

Side Effects and Safety Considerations

Like all effective medicines, dupilumab can cause unwanted effects. The most common side effect is a reaction at the injection site, such as redness, swelling, or pain. Inflammation of the eye and eyelid, including conjunctivitis and dry eye, occurs more frequently in patients taking dupilumab than in those taking a placebo, especially in those treated for atopic dermatitis. Some individuals may experience cold sores on the lips or skin due to herpes virus reactivation. A temporary increase in the number of certain white blood cells, called eosinophils, has been observed, and rarely this can be associated with symptoms or new conditions like eosinophilic pneumonia or vasculitis. Allergic reactions to the medicine itself, including a few cases of serum sickness-like reactions, have been reported. Joint pain and muscle aches are also possible. These safety findings are drawn from the drug’s prescribing information and pooled analyses of multiple studies. Prescribers monitor patients for these potential issues during treatment.

Long-Term Health Impact

Because dupilumab has been in use for less than a decade, understanding of its long-term effects continues to grow. Data from extension studies that followed patients for up to five years suggest that the medicine maintains its effectiveness over time without new or increasing safety signals. For instance, a long-term open-label study in adults with atopic dermatitis found that the rates of common side effects like conjunctivitis and injection site reactions remained stable and manageable, and no new safety concerns emerged. Ongoing surveillance through registries and post-marketing reports helps identify rare events. Overall, the current evidence indicates that for appropriately selected individuals, the health gains from controlling severe type 2 inflammatory diseases outweigh the known risks, although each person’s situation requires individualized assessment.

Conclusion

Dupilumab represents a targeted approach to managing a group of chronic conditions that share an underlying immune pathway. By blocking key inflammatory messengers, it can bring substantial relief from skin lesions, breathing difficulties, nasal blockages, swallowing problems, and debilitating itch. Side effects are generally mild or manageable, but careful monitoring is necessary. As more is learned about its long-term use, the role of dupilumab in improving the health and daily lives of people with type 2 inflammatory diseases becomes increasingly clear.

Sources

U.S. Food and Drug Administration. Dupixent (dupilumab) injection, for subcutaneous use. Prescribing information. Regeneron Pharmaceuticals, Inc. Revised 2023.
Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335-2348.
Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med. 2018;378(26):2486-2496.
Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps: results from two randomized controlled trials. Lancet. 2019;394(10209):1638-1650.
Dellon ES, Rothenberg ME, Collins MH, et al. Dupilumab in adults and adolescents with eosinophilic esophagitis. N Engl J Med. 2022;387(25):2317-2330.
FDA approves Dupixent (dupilumab) for prurigo nodularis. U.S. Food and Drug Administration news release, September 2022.
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis: a 5-year open-label extension study. JAMA Dermatol. 2022;158(9):1040-1048.

(Source : DeepSeek)

Introduction

Many antihistamines can relieve allergy symptoms, but they do not all behave in the same way inside the body. Bilastine is a newer second-generation antihistamine designed to provide effective relief from allergic conditions while minimizing some of the unwanted effects associated with older allergy medicines. Its main distinguishing features are its low potential for drowsiness, limited drug interactions, strong selectivity for histamine H1 receptors, and convenient once-daily dosing.

A Modern Antihistamine Designed to Avoid Sedation

One of the main advantages of bilastine is its low tendency to cause sleepiness. Older antihistamines, especially first-generation drugs such as diphenhydramine, can easily enter the brain and block histamine receptors involved in wakefulness. This can lead to drowsiness, reduced attention, and slower reaction times.

Bilastine belongs to the second generation of antihistamines, which were developed to reduce these effects. It has very limited ability to cross the blood–brain barrier, meaning that much less of the drug reaches the brain. Because of this, bilastine generally produces little or no significant impairment of alertness or cognitive performance when taken at the recommended dose.

Clinical studies comparing bilastine with placebo and other antihistamines have shown that it has a similar level of sedation to placebo and a lower sedative effect than many older antihistamines.

A Highly Selective Blocker of Histamine H1 Receptors

Bilastine works by selectively blocking histamine H1 receptors. Histamine is a chemical messenger released during allergic reactions that causes symptoms such as itching, sneezing, runny nose, watery eyes, and hives.

By occupying H1 receptors before histamine can activate them, bilastine prevents many of the effects responsible for allergy symptoms. Its high selectivity means that it mainly targets the receptor involved in allergies while having fewer effects on other receptors that can contribute to side effects.

This receptor selectivity contributes to its favorable safety profile compared with some older antihistamines that affect multiple systems in the body.

A Low Potential for Drug Interactions

Another feature that makes bilastine different from many medications is the way the body processes it. Unlike many drugs, bilastine is not significantly broken down by the liver cytochrome P450 enzyme system, which is responsible for metabolizing many medications.

Because of this, bilastine has a relatively low potential for interactions with other drugs that rely on these enzymes. This can make it a useful option for people who take multiple medications, although individual medical situations should always be evaluated by a healthcare professional.

The Main Limitation: Food Reduces Absorption

Although bilastine has several advantages, it has an important administration requirement. Food, especially fruit juices such as grapefruit, orange, and apple juice, can significantly reduce the amount of bilastine absorbed into the bloodstream.

For this reason, bilastine is usually recommended to be taken on an empty stomach, at least one hour before eating or two hours after a meal or fruit juice. Following this timing allows the body to absorb the expected amount of medicine and maintain reliable symptom control.

Effective Relief for Allergic Rhinitis and Urticaria

Bilastine has been extensively studied for allergic rhinitis and chronic spontaneous urticaria. Clinical trials have shown that a daily 20 mg dose can reduce symptoms such as sneezing, nasal itching, runny nose, and itchy eyes in people with allergic rhinitis.

In people with chronic spontaneous urticaria, bilastine has been shown to reduce itching and the number of hives, improving daily comfort and sleep quality. Its effectiveness has been found to be comparable to other modern antihistamines such as cetirizine, levocetirizine, and desloratadine.

A Favorable Balance Between Effectiveness and Tolerability

The main reason bilastine stands out is its balance between effectiveness and tolerability. It provides strong antihistamine activity without many of the problems historically associated with allergy medicines, particularly sedation and frequent drug interactions.

Like all medications, bilastine can still cause side effects. Headache, dizziness, fatigue, or mild drowsiness may occur in some people, although these effects are generally uncommon. It is also not suitable for everyone, particularly people with certain kidney problems or specific medical conditions without medical advice.

Conclusion

Bilastine represents a modern approach to allergy treatment. Its combination of strong H1 receptor blocking activity, low brain penetration, limited drug interaction potential, and once-daily dosing makes it a distinctive option among second-generation antihistamines.

Its main disadvantage is the need to avoid food and certain fruit juices around the time of administration. When taken correctly, bilastine provides effective relief from allergic rhinitis and urticaria while maintaining a low risk of sedation and other unwanted effects.

Sources

Bachert C, Kuna P, Sanquer F, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy. 2009;64(1):158-165.

Kuna P, Bachert C, Nowacki Z, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis. Allergy. 2009;64(2):293-299.

Zuberbier T, Oanta A, Bogacka E, et al. Comparison of the efficacy and safety of bilastine 20 mg vs levocetirizine 5 mg for the treatment of chronic idiopathic urticaria. Allergy. 2010;65(4):516-528.

Sastre J, Mullol J, Valero A, et al. Bilastine: an updated review of its clinical pharmacology and clinical use. Drugs in Context. 2018;7:212535.

García-Gea C, Ballester MR, Antonijoan RM, et al. A thorough QT/QTc study with bilastine in healthy subjects. International Journal of Clinical Practice. 2014;68(2):244-252.

Tyl B, Kabbaj M, Azzam S, et al. Lack of effect of food and grapefruit juice on the pharmacokinetics of bilastine, a novel non-sedating antihistamine. Clinical Therapeutics. 2012;34(5):1159-1169.

Conen S, Theunissen EL, Van Hecken A, et al. Acute effects of bilastine, a non-sedating H1-antihistamine, on cognitive and psychomotor function compared with hydroxyzine and placebo. Journal of Psychopharmacology. 2011;25(11):1517-1525.

(Source : ChatGPT)